APA (7th ed.) Citation

T, H., R, M., A, H., K, S., P, B., N, K., & J, S. (2025). On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic information. Frontiers in immunology, 16, 1599143. https://doi.org/10.3389/fimmu.2025.1599143

Chicago Style (17th ed.) Citation

T, Hattenhauer, Mispelbaum R, Heine A, Schwab K, Brossart P, Klümper N, and Saal J. "On-treatment Modified Glasgow Prognostic Score (mGPS) in Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab Provides Prognostic Information." Frontiers in Immunology 16 (2025): 1599143. https://doi.org/10.3389/fimmu.2025.1599143.

MLA (9th ed.) Citation

T, Hattenhauer, et al. "On-treatment Modified Glasgow Prognostic Score (mGPS) in Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab Provides Prognostic Information." Frontiers in Immunology, vol. 16, 2025, p. 1599143, https://doi.org/10.3389/fimmu.2025.1599143.